Amarin Corp Plc (AMRN)

[no_mo_Butterfinger]

Not forgetting insurance companies at all. If Lovaza was able to get such a HUGE percentage of their usage off label, then so should Vascepa.
But that's not happening because its not getting prescribed, pure & simple. Higher priced generics just took 1/2 their business for crying out loud.
From day one we expected our superior product to just step right into Lovaza business & waltz away with it in both direct & off-label use. And now we're supposed to expect that ANCHOR will succeed? There was a time I thought so, but that was a different time indeed.
PS I am using off-label w/ BC/BS with no problem.
Excuses are getting thin.